Article
CYP2C19 Phenotype, P2Y12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy.
Journal of the American Heart Association - 15 Jul 2025
Patel Rajiv C, Thomas Cameron D, Rossi Joseph S, Franchi Francesco, Keeley Ellen C, Beitelshees Amber L, Duarte Julio D, Ortega-Paz Luis, Kulick Natasha, Winget Marshall, Nguyen Anh B, Yang William E, Venkatesh Sanjay, Angiolillo Dominick J, Cavallari Larisa H, Lee Craig R, Stouffer George A
Abstract excerpt
BACKGROUND: Use of CYP2C19 genotyping to guide antiplatelet therapy is associated with improved clinical outcomes in patients naïve to P2Y12 inhibitors undergoing percutaneous coronary intervention. The relationship between CYP2C19 genotype and clinical outcomes in patients on maintenance clopidogrel at the time of percutaneous coronary intervention is unknown. METHODS: This was a retrospective, multicenter...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.